*MG2401 is an alternative to Clozapine which is based upon novel, IP free scaffolds and ring systems.

Approximately 67,000 patients in the United States are prescribed clozapine each year. Despite its effectiveness, clozapine is underutilized due to concerns about side effects and the burdens of monitoring requirements.

The global clozapine market was valued at approximately $1.5 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 5.7%, reaching around $2.6 billion by 2032. This growth is driven by the increasing prevalence of schizophrenia and bipolar disorder, as well as the need for effective treatment options for patients who do not respond to standard antipsychotic medications.

Actyon is seeking partnerships for this program.